[
  {
    "ts": null,
    "headline": "FDA awards cancer drug approvals to AbbVie and MSD",
    "summary": "The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.",
    "url": "https://finnhub.io/api/news?id=9c23820bf213f9805c850c6509c405e1aa7de43595bfeef3e8a12fb3d2a15ebe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747337178,
      "headline": "FDA awards cancer drug approvals to AbbVie and MSD",
      "id": 134483574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.",
      "url": "https://finnhub.io/api/news?id=9c23820bf213f9805c850c6509c405e1aa7de43595bfeef3e8a12fb3d2a15ebe"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma",
    "summary": "The Food and Drug Administration approved belzutifan, or Welireg, marketed by Merck (MRK), for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma, or PPGL. “This represents the first FDA approval of an oral therapy for PPGL,” the FDA stated. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on M",
    "url": "https://finnhub.io/api/news?id=a469a656d247faded95dd3b79fb1a3d54d43686dee29def2c8cbb46e8f75638f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747325152,
      "headline": "FDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma",
      "id": 134483654,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Food and Drug Administration approved belzutifan, or Welireg, marketed by Merck (MRK), for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma, or PPGL. “This represents the first FDA approval of an oral therapy for PPGL,” the FDA stated. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on M",
      "url": "https://finnhub.io/api/news?id=a469a656d247faded95dd3b79fb1a3d54d43686dee29def2c8cbb46e8f75638f"
    }
  },
  {
    "ts": null,
    "headline": "Jefferies not seeing significant impact to Merck, Bristol from draft guidance",
    "summary": "Jefferies analyst Akash Tewari notes that new Medicare Part B & D draft guidance has been released and that Merck (MRK) and Bristol Myers (BMY) are trading down due to updated language on single source qualifying drugs. The updated language on single source qualifying fixed dose combo products in the draft makes it seem as if subcutaneous Keytruda/Opdivo will be eligible for negotiation in 2028, but “We’re not sure this is true,” says the analyst, who is not seeing a significant impact to Merck",
    "url": "https://finnhub.io/api/news?id=a5e23610b27ea36bddd804267019ff16d2b16141897332c37609c40a079c1a32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747320402,
      "headline": "Jefferies not seeing significant impact to Merck, Bristol from draft guidance",
      "id": 134483656,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Jefferies analyst Akash Tewari notes that new Medicare Part B & D draft guidance has been released and that Merck (MRK) and Bristol Myers (BMY) are trading down due to updated language on single source qualifying drugs. The updated language on single source qualifying fixed dose combo products in the draft makes it seem as if subcutaneous Keytruda/Opdivo will be eligible for negotiation in 2028, but “We’re not sure this is true,” says the analyst, who is not seeing a significant impact to Merck",
      "url": "https://finnhub.io/api/news?id=a5e23610b27ea36bddd804267019ff16d2b16141897332c37609c40a079c1a32"
    }
  },
  {
    "ts": null,
    "headline": "Building A SCHD Inspired Dividend Income Screener For May",
    "summary": "Building A SCHD Inspired Dividend Income Screener For May",
    "url": "https://finnhub.io/api/news?id=4d3728aa099c7090d26f62b78061b4d0088d4de0861fa23bb6f8ad23b1b93f79",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747312653,
      "headline": "Building A SCHD Inspired Dividend Income Screener For May",
      "id": 134476841,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4d3728aa099c7090d26f62b78061b4d0088d4de0861fa23bb6f8ad23b1b93f79"
    }
  },
  {
    "ts": null,
    "headline": "UK's MHRA Approves Vaccine To Protect Against Pneumococcal Infections Like Pneumonia & Meningitis",
    "summary": "UK's MHRA: * UK'S MHRA: APPROVES VACCINE TO PROTECT AGAINSTPNEUMOCOCCALINFECTIONS SUCH AS PNEUMONIA AND MENINGITIS - WEBSITE * UK'S MHRA: APPROVED CAPVAXIVE FOR PEOPLE...",
    "url": "https://finnhub.io/api/news?id=b168f110202c41432a2145c25bd71bbbb59afe01944ab56c7741958ccf49be29",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747311488,
      "headline": "UK's MHRA Approves Vaccine To Protect Against Pneumococcal Infections Like Pneumonia & Meningitis",
      "id": 134474541,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "UK's MHRA: * UK'S MHRA: APPROVES VACCINE TO PROTECT AGAINSTPNEUMOCOCCALINFECTIONS SUCH AS PNEUMONIA AND MENINGITIS - WEBSITE * UK'S MHRA: APPROVED CAPVAXIVE FOR PEOPLE...",
      "url": "https://finnhub.io/api/news?id=b168f110202c41432a2145c25bd71bbbb59afe01944ab56c7741958ccf49be29"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers",
    "summary": "RAHWAY, N.J., May 15, 2025--Merck Announces Positive Topline Results of Phase 3 KEYNOTE-B96 Trial In Patients With Platinum-Resistant Recurrent Ovarian Cancer",
    "url": "https://finnhub.io/api/news?id=f243f56b24b50df6c0dc35302501744fa40b7a9dadf211d195d4a0ff9305af7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747305900,
      "headline": "Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers",
      "id": 134465704,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., May 15, 2025--Merck Announces Positive Topline Results of Phase 3 KEYNOTE-B96 Trial In Patients With Platinum-Resistant Recurrent Ovarian Cancer",
      "url": "https://finnhub.io/api/news?id=f243f56b24b50df6c0dc35302501744fa40b7a9dadf211d195d4a0ff9305af7d"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Oracle, IBM, Merck and Earth Science Tech",
    "summary": "Oracle, IBM, Merck and Earth Science Tech are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=5dd7b5d37a60f1ae2e7821d77ca6da41d8685708393f3195021fc079999ac5b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747304220,
      "headline": "The Zacks Analyst Blog Highlights Oracle, IBM, Merck and Earth Science Tech",
      "id": 134483613,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Oracle, IBM, Merck and Earth Science Tech are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=5dd7b5d37a60f1ae2e7821d77ca6da41d8685708393f3195021fc079999ac5b3"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival in Patients with Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers",
    "summary": "Merck announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival for the treatment of patients with platinum-resistant recurrent...",
    "url": "https://finnhub.io/api/news?id=491c0e5b8498e2ebb588cd6ad552c72aa1e9a15fa9bd7aab940f7d319efe8d9f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747291500,
      "headline": "Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival in Patients with Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers",
      "id": 134465828,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its primary endpoint of progression-free survival for the treatment of patients with platinum-resistant recurrent...",
      "url": "https://finnhub.io/api/news?id=491c0e5b8498e2ebb588cd6ad552c72aa1e9a15fa9bd7aab940f7d319efe8d9f"
    }
  }
]